African Vaccine Sovereignty: From Continental Ambition to Operational Capacity

Africa can now fill-finish nearly 2 billion vaccine doses per year; antigen production - the biological core of the vaccine - remains very limited. The continent can bottle vaccines it does not yet know how to manufacture. This gap sums up the challenge of African vaccine sovereignty, which now rests on a quantified objective, an institutional framework and a dedicated financing mechanism, but whose effective operational capacity remains to be demonstrated. The continent accounts for a marginal share of global supply - around 0.1% of doses manufactured, with less than 1% of the doses administered on its soil produced there. The Bundibugyo Ebola outbreak declared in the Democratic Republic of Congo and Uganda in May 2026, for which no licensed vaccine exists and whose candidates depend on production chains outside the continent, translates that gap directly into a health risk.

This note analyzes the structural drivers of dependence, assesses the existing manufacturing base against its constraints, and sets out public-policy directions around five levers: antigen production, governance of technology transfers, human capital, regulatory maturity and market guarantees. It concludes that the current trajectory is real, but that its success depends on converting a continental objective into end-to-end controlled production chains, a process whose horizon extends beyond current funding cycles.

Strategic Context

African supply vulnerability stems less from insufficient demand than from a failure of supply and markets. Demand is established and can be made solvent: more than one billion dollars per year for around 1.3 billion doses annually. Local supply, by contrast, remains residual, exposing the continent to a systemic risk of shortages during periods of global stress. The COVID-19 pandemic materialized this risk: placed at a disadvantage in global dose allocation, the continent saw around 32 million locally fill-finished doses shipped abroad, showing that industrial capacity alone does not guarantee priority access.

This dependence also has a human and fiscal dimension. Medical brain drain is estimated at around 2 billion dollars per year, a transfer of value that weakens the sustainability of health systems and the creation of an endogenous knowledge base. The imbalance can therefore be read as an asymmetric transfer of knowledge and productive capacity, whose correction requires coordinated action on upstream industry, financing and regulation, not merely the import of finished products.

Case Analysis: Africa's Manufacturing Base and Its Variables

Vaccine sovereignty is not starting from a blank page. At the end of 2024, five suppliers in four countries had industrial-scale facilities - Aspen and Biovac in South Africa, Institut Pasteur de Dakar in Senegal, Marbio in Morocco and Vacsera in Egypt, with eight of fifty-four countries having production capacity. Institut Pasteur de Dakar is the operational benchmark: it has produced a yellow fever vaccine since 1937, remains the only African manufacturer of a WHO-prequalified vaccine, and its regulatory authority has obtained ML3 maturity accreditation. At continental scale, mapping has identified 574 active manufacturers, including 25 involved in vaccine production, and more than 30 manufacturing initiatives are under way.

This real base must be assessed against a decisive technological asymmetry. Fill-finish capacity is already close to 2 billion doses, while local antigen production, the biological core of the vaccine, remains very limited. African capacity is therefore concentrated on downstream value-chain segments, where technological barriers are lower, and remains dependent on upstream production. This configuration explains the gap between apparent autonomy, measured in filled-finished doses, and real autonomy, which requires end-to-end control of the process. There is still a marked distance between proven capacity for established products and the urgent manufacture of a vaccine against an emerging strain.

Policy Pillars and Recommendations

The target set by the African Union - to produce locally 60% of vaccine needs by 2040, carried by the PAVM initiative led by the Africa Centres for Disease Control and Prevention - will only be achieved by acting simultaneously on five structural levers.

1. Internalize antigen production. Investment priorities must shift from fill-finish toward production of the active substance. As long as antigen remains imported, fill-finish capacity is not a guarantee of supply security. The objective of WHO prequalification for eight locally manufactured vaccines by 2030 requires vertical integration that is still marginal today.

2. Govern technology transfers. Most current and planned capacities do not have secured technology transfer. Without a contractual framework that guarantees ownership of the process, technology transfer risks replacing commercial dependence with technological dependence. The thirteen transfer agreements concluded in six countries under recent mechanisms must be assessed against this benchmark.

3. Consolidate human capital. Scaling up requires a skilled workforce whose training timeline exceeds the infrastructure calendar. The establishment in Senegal of a center designed to train 9,000 to 14,000 people sets a precedent that should be generalized and aligned with actual industrial needs.

4. Harmonize regulation. Prequalification requires mature national regulatory authorities. Eight authorities have reached WHO maturity level 3, but only Egypt, Nigeria and South Africa operate at the level required for prequalification. Cross-border regulatory integration remains incomplete: 27 of 54 countries have ratified the African Medicines Agency treaty, an insufficient threshold for establishing a single medicines market.

5. Guarantee the market. Industrial investment - around 200 million dollars for a plant on the scale of Institut Pasteur de Dakar - does not offer automatic profitability. The African Vaccine Manufacturing Accelerator, endowed with up to 1.2 billion dollars over ten years and based on a supplement of about 0.50 dollar per dose produced, aims to support production of more than 800 million doses by 2035; it was complemented by an AVMA+ envelope of 189 million dollars proposed in May 2026. These instruments should be read as public-private ecosystem dynamics correcting a market failure, not as guarantees of results: purchase support for African vaccines remains limited compared with Indian or Brazilian trajectories, where public procurement preceded industrial consolidation.

Institutional Challenges and Conclusion

The Bundibugyo outbreak isolates two distinct limits. The first, scientific and global, is the absence of a product: no vaccine has ever been licensed for this species, with the two available vaccines targeting Zaire virus without cross-immunity, and candidates in development, including an mRNA vaccine, not yet available. The second, industrial, directly concerns sovereignty: the manufacturing chain that can be mobilized is largely outside Africa. The possible availability of Ervebo, a licensed vaccine against Zaire virus considered on an exceptional basis, within an estimated timeline of around two months should not be confused with a rapid resolution of the outbreak: according to the WHO representation in the DRC, this timeline does not prejudge the end of the epidemic, the previous major outbreak having lasted nearly two years.

African vaccine sovereignty has a quantified target, an institutional framework and structuring finance. Moving from less than 1% to 60% local production in under two decades remains a wager, but the momentum is documented. The gap between ambition and operational capacity nevertheless persists: producing locally means mastering antigen, technology, skills, markets and autonomous regulation - levers that are built neither in isolation nor in the short term. The continent has the market, the demographic momentum and the epidemiological urgency; what remains to be demonstrated is its capacity to convert a continental objective into effective and resilient production chains.